Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Key Takeaways Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease ...

Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.

Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.

Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...

Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical ...

Regeneron (NASDAQ:REGN) and Sanofi (NASDAQ:SNY) announced Friday that the U.S. FDA approved a label expansion for its asthma therapy Dupixent (dupilumab) for certain patients with chronic ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...

Recommended Reading Alnylam wins FDA approval of rare disease drug in step toward profitability The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s ...

Regeneron REGN0.26%increase; green up pointing triangle Pharmaceuticals and Sanofi SAN 0.65%increase; green up pointing triangle have won U.S. Food and Drug Administration expanded approval of ...